Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TARZAN Trial: Tazemetostat, Zanubrutinib, and Anti-CD20 mAb in Relapsed/Refractory Indolent B-cell NHL
NCT06824701Phase 1Active, not recruiting
- Sponsor
- University of Utah
- Start
- Sep 2025
- Primary completion
- Jan 2032
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tazemetostat in B-cell non-Hodgkin lymphoma, sponsored by University of Utah. Primary endpoint: Maximum Tolerated Dose at 2 years. Started Sep 2025; status: active, not recruiting.
02
Drugs
tazemetostat
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT06824701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06824701.